Abcam, ab279727, Phospho-ABL1 (Y245) ELISA Kit

Size: 1 x 96Tests
Phospho-ABL1 (Y245) ELISA Kit is a Semi-quantitative ELISA for the measurement of Phospho-ABL1 (Y245) in Human in Cell/Tissue Extracts samples.
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate,
Reacts with:Human,
Assay type:Semi-quantitative,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Phospho-ABL1 (Y245) ELISA Kit (ab279727) is a very rapid, convenient, and sensitive assay kit that can monitor the activation or function of important biological pathways in human cell lysates. By determining phosphorylated ABL1 protein in your experimental model system, you can verify pathway activation in your cell lysates. You can simultaneously measure numerous different cell lysates without spending excess time and effort in performing a Western Blotting analysis.
This Sandwich ELISA kit is an
in vitro
enzyme-linked immunosorbent assay for the measurement of human phospho-ABL1. An anti-pan ABL1 antibody has been coated onto a 96-well plate. Samples are pipetted into the wells and ABL1 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and rabbit anti-phospho-ABL1 (Y245) antibody is used to detect phosphorylated ABL1. After washing away unbound antibody, HRP conjugated anti-rabbit IgG is pipetted into the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of ABL1 (Y245) bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ABL1 also referred to as ABL-1 or ABL1 protein is a non-receptor tyrosine kinase with a mass of approximately 120 kDa. It is found throughout the body in diverse tissues with significant expression in the brain testes and hematopoietic cells. This protein consists of several functional domains including SH3 SH2 and a kinase domain that facilitate its interaction with various cellular components. ABL1 kinase plays a central role in cell differentiation division and stress response reflecting its mechanical versatility in cellular signaling.
Biological function summary
ABL1 functions by regulating key processes like cell cycle progression actin dynamics and cell adhesion. ABL1 participates as part of larger protein complexes that modulate cellular movement and gene transcription. When activated it phosphorylates a range of substrates that leads to various cellular outcomes. ABL1 operates in the cytoplasm and nucleus influencing both cytoskeletal rearrangement and DNA repair which highlights its critical function in maintaining cellular integrity and response to damage.
Pathways
ABL1 interacts in both the mitogenic and apoptotic pathways including involvement in the MAPK and PI3K/AKT pathways. ABL1 interfaces with proteins like CRK and GRB2 in these pathways integrating signals that determine cell fate decisions. Through its kinase activity ABL1 mediates signaling cascades that impact cellular growth and survival responding dynamically to internal and external cues.
ABL1 is notoriously implicated in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The fusion protein BCR-ABL1 resulting from chromosomal translocation drives oncogenic signals that promote uncontrolled cell proliferation. The aberrant activity of BCR-ABL1 disrupts normal cellular regulation and interacts with proteins such as STAT5 enhancing leukemogenesis. Targeted therapies like tyrosine kinase inhibitors specifically hinder BCR-ABL1 activity demonstrating ABL1's importance in cancer pathology and treatment.